TAK - Ovarian Cancer Player ImmunoGen Can Potentially Be Attractive M&A Target: JP Morgan | Benzinga
JP Morgan upgraded ImmunoGen Inc (NASDAQ: IMGN) from Neutral to Overweight with a price target of $22, up from $9, based on insights gathered from a recent physician survey, which focused on the ongoing launch of Elahere (mirvetuximab soravtansine-gynx) in platinum-resistant ovarian cancer (PROC), as well as their assessment of IMGN's R&D portfolio.
The analysts Brian Cheng and Sungin Yun note strong confidence in the growth trajectory of Elahere's launch in the U.S.
Also Read: ImmunoGen Outperforms Q2 Revenue Expectations Bolstered By Strong Elahere Sales
The feedback received from the survey, which involved ...